|
1）Gross NJ, Skorodin M. Role of the parasympathetic system in airway obstruction due to emphysema. N Engl J Med. 1984; 311: 421-6
|
|
|
|
2）Donohue JF, van Noord JA, Bateman ED, et al. A 6-month placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or sal meterol. Chest. 2002; 122: 47-55
|
|
|
|
|
|
3）Vogelmeier C, Hederer B, Glaab T, et al; for the POET-COPD Investigators. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011; 364: 1093-103
|
|
|
|
|
|
4）日本呼吸器学会COPDガイドライン第3版作成委員会，編．COPD（慢性閉塞性肺疾患）診断と治療のためのガイドライン．第3版．東京：メディカルレビュー社；2009
|
|
|
|
|
|
5）Battram C, Charlton SJ, Cuenoud B, et al. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one（indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action. Pharmacol Exp Ther. 2006; 317(2): 762-70
|
|
|
|
|
|
6）Korn S, Kerwin E, Atis S, et al. Indacaterol once-daily provides superior efficacy to Salmeterol twice-daily in COPD: A 12-week study. Respir Med. 2011; 105: 719-26
|
|
|
|
|
|
7）Kornmann O, Dahl R, Centanni S, et al. Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir. 2011; 37: 273-9
|
|
|
|
|
|
8）Dahl R, Chung KF, Buhl R, et al; INVOLVE（INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety）Study Investigators. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010; 65(6): 473-9
|
|
|
|
|
|
9）Rossi A, Centanni S, Cerveri I, et al. Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium. Respir Med. 2012; 106(1): 84-90
|
|
|
|
|
|
10）Donohue JF, Fogarty C, Lotvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010; 182: 155–62
|
|
|
|
|
|
11）Buhl R, Dunn LJ, Disdier C, et al; INTENSITY study investigators. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J. 2011; 38(4): 797-803
|
|
|
|
|
|
12）Tashkin DP, Celli B, Senn S, et al; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008; 359(15): 1543-54
|
|
|
|
|
|
13）Peter MA, Calverley MD, Julie A, et al; for the TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007; 356: 775-89
|
|
|
|
|
|
14）The Global Initiative for Chronic Obstructive Lung Disease（GOLD）. http://www.goldcopd.org/
|
|
|
|
|
|
15）Barnes PJ, Stockley RA. COPD: current therapeutic interventions and future approaches. Eur Respir J. 2005; 25: 1084-106
|
|
|
|
|
|
16）Grootendorst DC, Gauw SA, Verhoosel RM, et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax. 2007; 62: 1081-7
|
|
|
|
|
|
17）Rabe KF, Bateman ED, O’Donnell D, et al. Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2005; 366: 563-71
|
|
|
|
|
|
18）Calverley PM, Sanchez-Toril F, McIvor A, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007; 176: 154-61
|
|
|
|
|
|
19）Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009; 374: 685-94
|
|
|
|
|
|
20）Rennard SI, Calverley PM, Goehring UM, et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast-the importance of defining different subsets of patients with COPD. Respir Res. 2011; 12: 18
|
|
|
|
|
|
21）Agusti A, Calverley PM, Celli B, et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints（ECLIPSE）investigators. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010; 11: 122
|
|
|
|
|